OBJECTIVE: Routine extrahepatic bile duct (EBD) resection in non-jaundiced patients with gallbladder cancer (GBC) is controversial. The aim of this study was to retrospectively analyse patterns of recurrence in patients who underwent resection of GBC without routine EBD resection. METHODS: This analysis referred to 58 patients who had undergone explorative laparotomy for GBC during 2000-2012 at a single, tertiary referral centre. Overall survival, time to recurrence, and patterns of recurrence were assessed in patients who underwent conventional negative-margin (R0) resection without routine EBD resection. RESULTS: Of 58 patients submitted to explorative laparotomy for GBC, 26 (45%) patients underwent R0 resection without EBD resection (tumour stage T1b in five patients, T2 in 17, T3 in three, and T4 in one). The 3-year survival rate among these patients was 78% at a median follow-up of 33 months (range: 13-127 months). Seven patients developed recurrent disease at a median of 9 months (range: 2-25 months) after resection. No patients developed isolated recurrent disease at the EBD. CONCLUSIONS: Of 26 patients resected for GBC, none developed isolated recurrent disease at the EBD after conventional resection of GBC without EBD resection. This finding suggests that routine EBD resection is of no additional value.
OBJECTIVE: Routine extrahepatic bile duct (EBD) resection in non-jaundicedpatients with gallbladder cancer (GBC) is controversial. The aim of this study was to retrospectively analyse patterns of recurrence in patients who underwent resection of GBC without routine EBD resection. METHODS: This analysis referred to 58 patients who had undergone explorative laparotomy for GBC during 2000-2012 at a single, tertiary referral centre. Overall survival, time to recurrence, and patterns of recurrence were assessed in patients who underwent conventional negative-margin (R0) resection without routine EBD resection. RESULTS: Of 58 patients submitted to explorative laparotomy for GBC, 26 (45%) patients underwent R0 resection without EBD resection (tumour stage T1b in five patients, T2 in 17, T3 in three, and T4 in one). The 3-year survival rate among these patients was 78% at a median follow-up of 33 months (range: 13-127 months). Seven patients developed recurrent disease at a median of 9 months (range: 2-25 months) after resection. No patients developed isolated recurrent disease at the EBD. CONCLUSIONS: Of 26 patients resected for GBC, none developed isolated recurrent disease at the EBD after conventional resection of GBC without EBD resection. This finding suggests that routine EBD resection is of no additional value.
Authors: Jason M Foster; Hisakazu Hoshi; John F Gibbs; Renuka Iyer; Miland Javle; Quyen Chu; Boris Kuvshinoff Journal: Ann Surg Oncol Date: 2006-11-11 Impact factor: 5.344
Authors: Michael D'Angelica; Kimberly Moore Dalal; Ronald P DeMatteo; Yuman Fong; Leslie H Blumgart; William R Jarnagin Journal: Ann Surg Oncol Date: 2008-11-05 Impact factor: 5.344
Authors: William G Hawkins; Ronald P DeMatteo; William R Jarnagin; Leah Ben-Porat; Leslie H Blumgart; Yuman Fong Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong Journal: Cancer Date: 2003-10-15 Impact factor: 6.860
Authors: Timothy M Pawlik; Ana Luiza Gleisner; Luca Vigano; David A Kooby; Todd W Bauer; Andrea Frilling; Reid B Adams; Charles A Staley; Eduardo N Trindade; Richard D Schulick; Michael A Choti; Lorenzo Capussotti Journal: J Gastrointest Surg Date: 2007-09-11 Impact factor: 3.452
Authors: Andrew J Sinnamon; Anthony C Wood; Megan A Satyadi; Catherine V Levitt; Olivia Hardy; Mintallah Haider; Richard D Kim; Daniel A Anaya; Jason W Denbo Journal: J Gastrointest Oncol Date: 2022-06